Home/Filings/4/0000950170-25-040314
4//SEC Filing

Treco Douglas A 4

Accession 0000950170-25-040314

CIK 0001693011other

Filed

Mar 16, 8:00 PM ET

Accepted

Mar 17, 4:24 PM ET

Size

8.0 KB

Accession

0000950170-25-040314

Insider Transaction Report

Form 4
Period: 2025-03-11
Treco Douglas A
DirectorCEO & Chairman
Transactions
  • Award

    Stock Option (right to buy)

    2025-03-11+400,000400,000 total
    Exercise: $1.06Exp: 2035-03-10Common Stock (400,000 underlying)
  • Award

    Restricted Stock Units

    2025-03-11+100,000100,000 total
    Common Stock (100,000 underlying)
Footnotes (3)
  • [F1]The exercise price represents the closing price of the Issuer's common stock on March 11, 2025.
  • [F2]The option was granted on March 11, 2025 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date.
  • [F3]The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028.

Documents

1 file

Issuer

Inozyme Pharma, Inc.

CIK 0001693011

Entity typeother

Related Parties

1
  • filerCIK 0001688192

Filing Metadata

Form type
4
Filed
Mar 16, 8:00 PM ET
Accepted
Mar 17, 4:24 PM ET
Size
8.0 KB